Skip to main content
. 2011 Aug 3;6(8):e23057. doi: 10.1371/journal.pone.0023057

Figure 2. High TGF-β signaling pathway activity is associated with decreased patient survival.

Figure 2

(A) Kaplan-Meier curves comparing disease-specific survival among 176 CCRCC patients divided into quartiles based on the TGF-β activity score. High TGF-β pathway activity score (76–100%) was significantly (log-rank, p = 0.006) associated with a worse disease-specific survival. (B) Immunohistochemical analyses using phospho-specific SMAD2 (pSMAD2) antibody of control (c) or SB431542 treated 786-O cells. Sections were counterstained with hematoxylin-eosin. Original magnification, ×40. (C) pSMAD2 is expressed in vivo. Immunohistochemistry of pSMAD2 in nine CCRCC tumors, that all showed positive nuclear staining. Sections were counterstained with hematoxylin-eosin. Original magnification, ×40.